Published in Osteoporos Int on June 08, 2010
Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis. Osteoporos Int (2012) 0.96
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int (2013) 0.94
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos (2016) 0.92
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int (2013) 0.92
Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX. J Bone Miner Metab (2015) 0.76
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int (2013) 0.75
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clinicoecon Outcomes Res (2015) 0.75
Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int (2012) 0.75
Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain. Clinicoecon Outcomes Res (2013) 0.75
Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model. Osteoporos Int (2016) 0.75
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ (1998) 8.27
Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 7.14
Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA (2009) 5.60
Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71
Risk of mortality following clinical fractures. Osteoporos Int (2000) 3.76
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
Natural history of venous thromboembolism. Circulation (2003) 3.67
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
Swedish population health-related quality of life results using the EQ-5D. Qual Life Res (2001) 2.87
Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br (1998) 2.82
The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81
The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2007) 2.75
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone (2005) 2.66
The components of excess mortality after hip fracture. Bone (2003) 2.63
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res (2000) 2.55
What is the true mortality of hip fractures? Public Health (1991) 2.52
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (2003) 2.51
Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int (2007) 2.46
Alcohol intake as a risk factor for fracture. Osteoporos Int (2004) 2.34
Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ (2000) 2.27
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) (2000) 2.13
Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int (2005) 2.05
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ (1997) 1.71
Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res (1995) 1.69
The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int (1994) 1.46
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone (2009) 1.41
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36
Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int (2000) 1.35
Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int (2007) 1.33
The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry (2006) 1.28
Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess (2002) 1.26
Lifetime risk of hip fractures is underestimated. Osteoporos Int (1998) 1.15
Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop (2008) 1.08
Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. Osteoporos Int (2007) 1.00
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int (2004) 0.99
The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost (2003) 0.99
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int (2006) 0.96
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int (2006) 0.96
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer (2006) 0.94
Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ (2006) 0.90
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics (2004) 0.84
Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care (2005) 0.79
Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl (1996) 0.79
Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. Curr Med Res Opin (2005) 0.78
Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas (1997) 0.76
Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res (2004) 0.76
[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective]. Lakartidningen (2003) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
15-year longitudinal study of blood pressure and dementia. Lancet (1996) 6.44
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst (1995) 3.79
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Bone densitometry in clinical practice. BMJ (1995) 3.48
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer (1997) 2.86
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet (2002) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer (1998) 2.51
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg (2002) 2.41
Bone-density measurement. Lancet (1992) 2.38
Influence of hospital- and surgeon-related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. Br J Surg (1997) 2.21
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys (1992) 2.09
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02
Increased risk of death from primary hyperparathyroidism--an update. Eur J Clin Invest (1998) 1.93
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat (2009) 1.90
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81
Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res (1995) 1.79
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer (1990) 1.73
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J (2007) 1.71
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg (2005) 1.68
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand Suppl (1983) 1.63
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer (1995) 1.60
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Position sense acuity is diminished following repetitive low-intensity work to fatigue in a simulated occupational setting. Eur J Appl Physiol (2000) 1.57
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg (2013) 1.56
A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum (1991) 1.56
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin (2013) 1.55
Protective effect of breastfeeding against urinary tract infection. Acta Paediatr (2004) 1.54
Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol (1999) 1.53
Effect of antiretroviral treatment and counselling on disclosure of HIV-serostatus in Johannesburg, South Africa. AIDS Care (2006) 1.52
Estimation of the parenchymal-cell content of the parathyroid gland, using density-gradient columns. Preliminary report. Acta Pathol Microbiol Scand A (1977) 1.52
Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys (1996) 1.50
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Use of diphosphonates in hypercalcaemia due to malignancy. Lancet (1990) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int (1994) 1.46
A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med (1994) 1.46
Using a logistic model to identify women with first-trimester spontaneous abortion suitable for expectant management. Br J Obstet Gynaecol (1996) 1.46
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) (1985) 1.45
The breech presentation and the vertex presentation following an external version represent risk factors for neonatal hip instability. Acta Paediatr (2001) 1.43
Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int (1997) 1.43
Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med (2006) 1.43